Epigenomic labeling of cells that drive drug abuse behavior

驱动药物滥用行为的细胞的表观基因组标记

• 批准号: 10293229
• 负责人: William Russell Renthal
• 金额: $ 53.7万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10293229
• 关键词: Affect; Animal Model; Bar Codes; Behavior; Cell Nucleus; Cells; Cessation of life; Chromatin; Chronic; Development; Drug Prescriptions; Drug abuse; Elements; Enhancers; Environment; Exposure to; Gene Expression; Genes; Genomic Segment; Knowledge; Label; Libraries; Life; Maps; Medical Care Costs; Modeling; Morphine; Mus; Nature; Neurons; Nucleus Accumbens; Opioid; Patients; Population; Rapid screening; Refractory; Regulator Genes; Regulatory Element; Relapse; Resolution; Respiratory Failure; Self Administration; Stimulus; Technology; Transgenic Mice; Translating; United States; Viral; Work; addiction; base; brain reward regions; chronic pain patient; drug abstinence; drug seeking behavior; epigenomics; improved; in vivo; innovation; novel; novel strategies; novel therapeutic intervention; opioid use; opioid use disorder; pain relief; side effect; transcriptome sequencing

PROJECT SUMMARY In an effort to provide pain relief to tens of millions of patients with chronic pain, opioids are one of the most commonly prescribed medications in the United States. Large segments of the population are thus exposed to the detrimental side effects of opioids, which can be life threatening and include addiction and respiratory failure. Compulsive opioid use despite these negative consequences defines opioid use disorder, a condition that is responsible for nearly 50,000 deaths and $80 billion in medical costs annually. Thus, there is an urgent need for the development of improved treatments for opioid use disorder. One of the greatest challenges in treating opioid use disorder is its chronic nature with patients often relapsing after long periods of drug abstinence. Persistent epigenomic changes in the nucleus accumbens of patients with opioid use disorder are thought to contribute to its chronic, relapsing course. It has remained challenging, however, to translate this knowledge into novel therapeutic approaches because it has not been possible to selectively target the epigenomically-modified neurons involved in drug-seeking behavior without also affecting nearby cells in unrelated circuits. Here we present an innovative approach to label cells that drive opioid-seeking behavior based on their unique epigenomic profile. To do this, we will first map at single-cell resolution, the regions of chromatin that are selectively accessible in mouse nucleus accumbens neurons after morphine self-administration, an established model of opioid use disorder. Some of these genomic regions will act as functional gene regulatory elements that activate gene expression (e.g. gene enhancers) after morphine self-administration. To identify these functional gene enhancers, we will generate an adeno-associated viral library in which each putative element promotes the expression of a unique barcode. We will then use single-nucleus RNA-sequencing to rapidly screen this viral library in vivo for the elements that selectively drive expression of their barcode in the nucleus accumbens neurons that have been epigenomically altered by morphine self-administration. The most selective viral candidate will be used to express inhibitory chemogenetic channels for controlling morphine-seeking behavior. Successful completion of this proposal will establish a fundamentally new approach to selectively label, purify, and control cells that drive opioid-seeking behavior. This approach offers a number of advantages over current state-of-the-art technologies including the ability to label cells involved in drug-seeking behavior without need for transgenic mice or precisely timed conditioned stimuli. By using evolutionarily-conserved gene regulatory elements to drive viral expression, this approach also has the potential to translate to patients with refractory opioid use disorder.

项目总结 在为数千万慢性疼痛患者提供疼痛缓解的努力中，阿片类药物是最 在美国常用的处方药。因此，人口的很大一部分人暴露在 阿片类药物的有害副作用，可能危及生命，包括成瘾和呼吸衰竭。 尽管有这些负面后果，但强制使用阿片类药物定义了阿片类药物使用障碍，一种情况是 每年造成近5万人死亡和800亿美元的医疗费用。因此，迫切需要 阿片类药物使用障碍的改进治疗的发展。 治疗阿片类药物使用障碍的最大挑战之一是其慢性性质，患者经常复发 在长期戒毒之后。慢性阻塞性肺疾病患者伏隔核持续性表观基因组学改变 阿片类药物使用障碍被认为是其慢性复发过程的原因之一。它仍然具有挑战性， 然而，要将这种知识转化为新的治疗方法，因为还不可能 选择性地靶向参与药物寻找行为的表观修饰神经元，而不影响 附近的细胞在无关的电路中。 在这里，我们提出了一种创新的方法来标记驱动阿片类药物寻求行为的细胞，基于其独特的 表观基因组图谱。要做到这一点，我们将首先以单细胞分辨率绘制染色质区域 吗啡自身给药后小鼠伏隔核神经元选择性可及 阿片类药物使用障碍模型。这些基因组中的一些区域将作为功能基因调控元件 在吗啡自我给药后激活基因表达(如基因增强剂)。要确定这些 功能基因增强子，我们将产生一个腺相关病毒库，其中每个假定的元件 促进唯一条形码的表达。然后我们将使用单核RNA测序来快速筛选 体内的这个病毒库寻找选择性地驱动其条形码在细胞核中表达的元件 被吗啡自身给药引起表观改变的伏隔核神经元。最挑剔的 候选病毒将用于表达控制吗啡寻求的抑制化学发生通道 行为。 该提案的成功完成将建立一种全新的方法来选择性地标记、净化 并控制驱动阿片类药物寻求行为的细胞。与当前的方法相比，这种方法具有许多优势 最先进的技术，包括标记参与毒品行为的细胞的能力，而不需要 转基因小鼠或精确定时的条件刺激。通过使用进化保守的基因调控 驱动病毒表达的因素，这种方法也有可能转化为难治性患者 阿片类药物使用障碍。